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On the obituary for
George E. Schreiner
To the Editor: Drs Robert Rubin and Christopher Blagg have
brought to my attention an error in my obituary for George
E. Schreiner where I wrote ‘He is credited with demonstrating
a patient on dialysis to a Senate Select Subcommittee.’1
In fact, he opposed this move, which he considered reckless,
but was persuaded to supply a dialysis machine and the assis-
tance of one of his nephrology fellows. A full account of this
can be read in the chapter on ‘Origins of the Medicare Kidney
Disease Entitlement: The Social Security Amendments of
1972’ by Retting2 and Schreiner.3
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Aldosterone blockade: the heart
versus the kidney
To the Editor: We read with great interest the recent
comprehensive review from Shavit et al.1 on aldosterone
blockade. Their summary of the data on glomerular ﬁltration
rate from eight available studies (six randomized controlled
studies in a total of 326 patients given spironolactone, one
using eplerenone in 268 patients, and one retrospective study)
in patients with an estimated glomerular ﬁltration rate
(eGFR) of 430ml/min per 1.73m2 suggests no signiﬁcant
difference in eGFR with either spironolactone or eplerenone
in addition to angiotensin-converting enzyme inhibitor or
angiotensin receptor blockers, but a detriment in patients
with resistant hypertension of approximately 7.4ml/min per
1.73m2. The argument for this may perhaps relate to the
putative beneﬁcial effects of blockade of the signaling pathway
mediating insulin resistance, ﬁbrosis, and proteinuria,
independent of changes in blood pressure.
Interestingly, Rossignol et al.2 have recently analyzed the
data from the Eplerenone EPHESUS study. In a subset of
5792 patients, with mean age 64 years, baseline eGFR
70±21ml/min per 1.73m2 (33% o60ml/min per 1.73m2),
and mean blood pressure 119/72mmHg, they noted that in
patients with left ventricular systolic dysfunction with or at
high risk of heart failure in the post-infarction setting, there
was an early change in eGFR, and after 24 months follow-up
they noted a gradual deterioration in eGFR ranging from the
baseline value of 4.6±0.9ml/min for those on eplerenone
(Po0.0001) to 2.7±0.9ml/min for those in the placebo
group (P¼ 0.02), giving a mean difference of 1.4±0.3
ml/min (Po0.0001). The difference occurred early within the
ﬁrst month of treatment and persisted, and was independent
of blood pressure changes, but may relate to changes in
hemodynamics based on plasma volume changes, perhaps
similar to the ﬁndings of Pisoni et al.3 in patients with
resistant hypertension given aldosterone blockade.
Most importantly, the observed decline in eGFR was not
clinically detrimental over a 2-year period. Indeed, addition of
eplerenone to standard care improved the clinical outcomes
despite the slightly greater early reductions in eGFR, com-
pared with placebo.
We believe it is therefore important to highlight these
recent ﬁndings to the reader and add to this excellent review,
and to stress the importance of long-term data on clinical
cardiovascular outcomes in chronic kidney disease.
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The Authors Reply: We appreciate the positive interest of
Professor Bhandari1 in our recently published comprehensive
review on ‘Aldosterone blockade in the management of
patients with CKD’.2 The study of Rossignol et al.3 constitutes
a post hoc analysis of the EPHESUS study4 and evaluated
the effect of eplerenone on renal function and the inter-
action between changes in renal function, and subsequent
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